Welcome to the EPA 2022 Interactive Programme 

The congress will officially run on Central European Summer Time (CEST/GMT +2) 

To convert the congress times to your local time Click Here 

 

Icon Description automatically generatedFully Live with Live Q&A Icon Description automatically generatedOn Demand (available from 4 June)  Icon Description automatically generatedECP Session Icon Description automatically generatedSection Session Icon Description automatically generated EPA Course (Pre-Registration Required) 

 

  Ask the Expert      Sessions with Voting      Live TV     Product Theatre

Displaying One Session

View

On Demand - Symposium 40: Treatment-Resistant Depression: The Real World Evidence

Session Type
Research
Date
Sat, 04.06.2022
Session Time
12:30 - 14:00
Room
On Demand 5
Session Description
Treatment resistant depression (TRD) is associated with severe impairment in cognitive functioning, increased risk of developing/being associated with comorbid illnesses, decreased workplace performance, increased risk of suicide, and increased cost of care TRD is becoming a major threat to public health because TRD prevalence represents at least 15–30% of MDD cases and MDD itself is one of the most commonly encountered mental disorders with a worldwide point prevalence rate of 4.7%. The speakers will present real life data from different European countries (Poland, Hungary – AS and ZF) and discuss possible new approaches to the TRD diagnosis and treatment (AH and JARQ).
Session Icon
On Demand

Treatment-Resistant Depression Revisited

Session Name
0290 - On Demand - Symposium 40: Treatment-Resistant Depression: The Real World Evidence (ID 102)
Session Type
Research
Date
Sat, 04.06.2022
Session Time
12:30 - 14:00
Room
On Demand 5
Session Icon
On Demand
Presenter
Lecture Time
12:30 - 12:50

Real-World Evidence from the Polish Study of Patients with Treatment-Resistant Depression: Patient Characteristics and Treatment Trajectories

Session Name
0290 - On Demand - Symposium 40: Treatment-Resistant Depression: The Real World Evidence (ID 102)
Session Type
Research
Date
Sat, 04.06.2022
Session Time
12:30 - 14:00
Room
On Demand 5
Session Icon
On Demand
Presenter
Lecture Time
12:50 - 13:10

Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-longz retrospective data analysis

Session Name
0290 - On Demand - Symposium 40: Treatment-Resistant Depression: The Real World Evidence (ID 102)
Session Type
Research
Date
Sat, 04.06.2022
Session Time
12:30 - 14:00
Room
On Demand 5
Session Icon
On Demand
Presenter
Lecture Time
13:10 - 13:30

Abstract

Introduction

Treatment-resistant depression (TRD) is associated with poor quality of life, elevated morbidity and mortality and high economic burden.

Our observational retrospective epidemiological study have estimated the rate of patients with TRD within a cohort of major depressive disorder (MDD) patients in Hungary and examine the comorbidities and mortality of patients with and without TRD.

Our study included patients with MDD who experienced new onset of depressive episode and received antidepressant prescription between 01 January 2009 and 31 August 2015, using data from nationwide, longitudinal database. A patient was considered to have TRD if two different antidepressant treatments had failed during a given pharmacologically treated periode.

Overall, 99,531 MDD patients were included, of which 8,268 (8,3%) met the criteria of TRD. Patients with TRD had significantly higher rate of having "Neurotic, stress-related and somatoform disorders", autoimmune disorders, cardio-or cerebrovascular diseases, thyroid disorders and suicide attempts than non-TRD patients (for all comparisons, p < 0,005).

Ths first study to assess the frequency of TRD in Hungary have found that the proportion of TRD is in the same range as in studies with similar methodology reported form other countries. The majority of our other main findings are also in line with previous studies from other countries.

Hide